Correlation Between PTP1B Expression and Organ Failure During Sepsis
NCT02295514 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 54
Last updated 2016-05-12
Summary
Despite major advances in the treatment and understanding of the pathophysiological mechanisms, mortality of severe sepsis remains high, ranging from 25 to 50%. With a prevalence \> 20% in intensive care units, it is now in a population increasingly aging with many co-morbidities, a real public health problem. Thus, changes in treatment to physiological axes could change the prognosis of these patients. Protein Tyrosine Phosphatase 1B (PTP1B) is involved in the negative regulation of many cellular pathways such as the response to insulin, leptin and certain growth factors and endothelial nitric oxide production. PTP1B appears to be particularly involved in the control of endothelial function and insulin secretion. Under these conditions, encouraging results have been obtained in a model of insulin resistance (obesity, diabetes) and as part of pro-angiogenic therapy by inhibition of PTP1B on models of heart failure. Recent advances have broadened the pathophysiological implications of PTP1B conferring a potential role in the regulation of inflammatory processes. In an experimental model of septic shock (Inserm 1096), the investigators demonstrated a significant improvement in survival and cardiovascular function in genetically deficient mice PTP1B (PTP1B - / -). Finally, PTP1B is involved in the downregulation of the signaling pathway of insulin via a feedback phenomenon. Septic shock induces many changes in carbohydrate metabolism. These changes result in hyperglycemia associated with insulin resistance, an independent risk factor of morbidity and mortality. Taken together, these data suggest that the expression of PTP1B could be useful in septic patients by modulating insulin resistance and thus the prognosis of these patients. This justifies the investigator clinical research project on the relationship between the expression of PTP1B levels, glycemic status and prognosis evaluated by the SOFA score in patients with septic shock with multiple organ failure.
Conditions
Interventions
- BIOLOGICAL
-
PTP1B dosage
PTP1B sampled and dosed during sepsis
Sponsors & Collaborators
-
Institut National de la Santé Et de la Recherche Médicale, France
collaborator OTHER_GOV -
University Hospital, Rouen
lead OTHER
Principal Investigators
-
steven grangé, MD · Rouen Universitary Hospital
Study Design
- Allocation
- NA
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-01-31
- Primary Completion
- 2016-05-31
- Completion
- 2016-05-31
Countries
- France
Study Locations
More Related Trials
-
Assessing Immune Dysfunction in Sepsis
NCT07154615 ·Status: RECRUITING
-
Study on the Construction and Application of Early Warning Model of Sepsis in Critically Ill Patients
NCT06904001 ·Status: ENROLLING_BY_INVITATION
-
Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient
NCT04105400 ·Status: UNKNOWN
-
Procalcitonin Monitoring May Decrease Antibiotic Use in the Intensive Care Unit
NCT01085994 ·Status: UNKNOWN
-
Regulation of Endocrine, Metabolic, Immune and Bioenergetic Responses in Sepsis
NCT00187824 ·Status: UNKNOWN
-
Study and Role of Inflammasome in Platelet Activation During Bacterial And/or Viral Sepsis
NCT06657781 ·Status: RECRUITING
-
The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis
NCT03340649 ·Status: UNKNOWN
-
Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis
NCT05229328 ·Status: UNKNOWN
-
Application of Stimulated Immune Response Change to Predict Outcome of Patient With Severe Sepsis
NCT02887274 ·Status: UNKNOWN
-
Descriptive Study of the Evolution in Proportion of Regulatory B Lymphocytes in Patients Hospitalized in Intensive Care for Severe Sepsis
NCT03115125 ·Status: UNKNOWN ·Phase: NA
-
Application of Biomarkers Change to Predict Outcome of Patient With Severe Sepsis
NCT02871895 ·Status: UNKNOWN
-
The Application of SERS and Metabolomics in Sepsis
NCT02213237 ·Status: UNKNOWN
-
The Early Coagulopathy for the Prognosis in Sepsis
NCT04582188 ·Status: UNKNOWN
-
Study of Procalcitonin (PCT)-Guided Antibiotic Use in Severe Sepsis Patients Without Obvious Infection
NCT01025180 ·Status: TERMINATED ·Phase: PHASE4
-
The Role of Dysfunctional HDL in Sepsis
NCT02934997 ·Status: COMPLETED
-
Prolonged Intravenous Infusion of β-lactam Antibiotics in Early Septic Patients
NCT05024565 ·Status: UNKNOWN ·Phase: NA
-
The Impact of Coagulation Disorders on the Diagnosis and Prognosis of Sepsis
NCT05998733 ·Status: UNKNOWN
-
Host Dysregulation-Driven Sepsis Prediction Model
NCT06523075 ·Status: COMPLETED
-
Evaluation of the Performance of a New Rapid Bacteremia Test in the Intensive Care Patient
NCT06241248 ·Status: COMPLETED
-
Evaluation of MorphoTEP With the FDG Among Patients in Severe Sepsis of Unspecified Etiology
NCT00791310 ·Status: UNKNOWN ·Phase: PHASE3
-
Identification of Cardiovascular and Molecular Prognostic Factors for the Mid- and Long-term Outcome of Sepsis
NCT03620409 ·Status: COMPLETED
-
A Prospective Observational Study of Sepsis
NCT05309889 ·Status: UNKNOWN
-
Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock
NCT02062970 ·Status: UNKNOWN ·Phase: NA
-
Mitochondrial Function in Septic Patients
NCT03748537 ·Status: COMPLETED ·Phase: NA
-
Expression of Protein Tyrosine Phosphatase 1B (PTP1B) and Body Composition Modification in Patients With Septic Shock
NCT03189355 ·Status: COMPLETED ·Phase: NA